<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464084</url>
  </required_header>
  <id_info>
    <org_study_id>2015P000857B</org_study_id>
    <secondary_id>R01DK102696</secondary_id>
    <nct_id>NCT03464084</nct_id>
  </id_info>
  <brief_title>Interaction of Melatonin With MTNR1B Genotype on Glucose Control - Study 2</brief_title>
  <official_title>Interaction of Melatonin and Light With MTNR1B Genotype on Glucose Control - Study 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to test the impact of melatonin and MTNR1B variation on regulation glucose
      regulation in a highly controlled in-laboratory setting and ex vivo in pancreatic islets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' recent GWAS discovery of MTNR1B as a novel type 2 diabetes gene has
      sparked great interest into the role of melatonin in glycemic control, for which the
      mechanism is largely unknown. This research will determine the effect of melatonin and MTNR1B
      on glycemic control under highly-controlled, in-laboratory protocols while manipulating
      circulating melatonin concentrations (both up and down) and assessing glycemic control by
      frequently-sampled intravenous glucose tolerance tests, as well as in ex vivo human
      pancreatic islets. This research will provide mechanistic insights into the metabolic effects
      of melatonin and the MTNR1B risk variant and may help in evidence-based approaches and
      personalized recommendations to improve glycemic control in night shift workers and
      late-night eaters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in glucose tolerance</measure>
    <time_frame>Day 1 of the three in-lab protocols</time_frame>
    <description>glucose responses to test meal compared across the three in-lab protocols</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in first-phase insulin release</measure>
    <time_frame>Day 1 of the three in-lab protocols</time_frame>
    <description>insulin responses to test meal compared across the three in-lab protocols</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Glucose</condition>
  <condition>Circadian Rhythm</condition>
  <condition>Melatonin</condition>
  <condition>Genes</condition>
  <condition>Light</condition>
  <arm_group>
    <arm_group_label>bright light placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>bright light melatonin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dim light</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Capsules containing microcrystalline cellulose</description>
    <arm_group_label>bright light placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>5 mg of melatonin per os.</description>
    <arm_group_label>bright light melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bright light</intervention_name>
    <description>room light will be bright</description>
    <arm_group_label>bright light placebo</arm_group_label>
    <arm_group_label>bright light melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dim light</intervention_name>
    <description>room light will be dim</description>
    <arm_group_label>dim light</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index: 20 and 35 kg/m2

          -  Age: 21-55 years of age

          -  Caucasian

          -  Non-smoking

          -  With regular sleep-wake cycle

          -  Passed medical and psychological screening tests

        Exclusion Criteria:

          -  Acute, chronic or debilitating medical conditions

          -  History of neurological or psychiatric disorder

          -  History of sleep disorder or regular use of sleep-promoting medication

          -  Current prescription, herbal, or over-the-counter medication use

          -  Traveling across 2 or more time zones within past 3 months

          -  Worked night or rotating shift work within past 1 year

          -  Drug or alcohol dependency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank AJL Scheer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frank AJL Scheer, PhD</last_name>
    <phone>6177327014</phone>
    <email>fscheer@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jingyi Qian, PhD</last_name>
    <phone>6175257423</phone>
    <email>jqian@bwh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Kelly</last_name>
      <phone>617-278-0662</phone>
      <email>lkelly17@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jingyi Qian</last_name>
      <phone>6175257423</phone>
      <email>jqian@bwh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>March 28, 2018</last_update_submitted>
  <last_update_submitted_qc>March 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Frank AJL Scheer, PhD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

